Abstract
Background: Postoperative adjuvant tamoxifen (TAM) therapy in breast cancer patients may lead, albeit rarely, to endometrial cancer. Preventive measures are urgently needed. Methods: The study subjects were postmenopausal women who had undergone surgery for breast cancer. The control group (n=10) received no further therapy. Patients who had completed adjuvant TAM therapy were assigned to a medroxy-progesterone acetate (MPA; 400 mg/day orally for 4 weeks) group (n=15) or no MPA treatment group (no MPA group) (n=15). Uterine cervix cytodiagnosis was performed after completing the TAM therapy (initial), and 4 (4-week) and 16 (16-week) weeks later. The serum 17β-estradiol (E2) and progesterone concentrations were measured initially and at 4 weeks. The karyopyknotic index (KPI), eosinophilic index (EI) and maturation index (MI) were calculated from Papanicolaou-stained specimens. Results: The background parameters showed no biases. There were no differences in the KPI or EI between the no MPA and MPA groups. However, regarding the MI, after 4 weeks in the MPA group, the intermediate cells were significantly increased, while the superficial cells tended to be significantly decreased. Regarding the percent change from the initial value, after 4 weeks in the MPA group, the KPI and superficial cells were significantly decreased, and the intermediate cells were significantly increased. The estrogen activity level and the progesterone concentration were significantly lower in the MPA group compared with the no MPA group. Conclusions. The MPA administration clearly lowered the estrogenic activity, indicating that MPA therapy should be effective in reducing the risk of TAM-associated endometrial cancer.
| Original language | English |
|---|---|
| Pages (from-to) | 25-31 |
| Number of pages | 7 |
| Journal | Breast Cancer |
| Volume | 3 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - Mar 1996 |
Fingerprint
Keywords
- Breast cancer
- Endometrial cancer
- Medroxyprogesterone acetate
- Tamoxifen
ASJC Scopus subject areas
- Radiology Nuclear Medicine and imaging
- Pharmacology (medical)
- Oncology
Cite this
Suppression of estrogenic activity by medroxyprogesterone acetate in tamoxifen-treated patients after surgery for breast cancer to reduce the risk of endometrial cancer development. / Doihara, Hiroyoshi; Takashima, Shigemitsu; Kurita, Akira; Moriwaki, Shosuke.
In: Breast Cancer, Vol. 3, No. 1, 03.1996, p. 25-31.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Suppression of estrogenic activity by medroxyprogesterone acetate in tamoxifen-treated patients after surgery for breast cancer to reduce the risk of endometrial cancer development
AU - Doihara, Hiroyoshi
AU - Takashima, Shigemitsu
AU - Kurita, Akira
AU - Moriwaki, Shosuke
PY - 1996/3
Y1 - 1996/3
N2 - Background: Postoperative adjuvant tamoxifen (TAM) therapy in breast cancer patients may lead, albeit rarely, to endometrial cancer. Preventive measures are urgently needed. Methods: The study subjects were postmenopausal women who had undergone surgery for breast cancer. The control group (n=10) received no further therapy. Patients who had completed adjuvant TAM therapy were assigned to a medroxy-progesterone acetate (MPA; 400 mg/day orally for 4 weeks) group (n=15) or no MPA treatment group (no MPA group) (n=15). Uterine cervix cytodiagnosis was performed after completing the TAM therapy (initial), and 4 (4-week) and 16 (16-week) weeks later. The serum 17β-estradiol (E2) and progesterone concentrations were measured initially and at 4 weeks. The karyopyknotic index (KPI), eosinophilic index (EI) and maturation index (MI) were calculated from Papanicolaou-stained specimens. Results: The background parameters showed no biases. There were no differences in the KPI or EI between the no MPA and MPA groups. However, regarding the MI, after 4 weeks in the MPA group, the intermediate cells were significantly increased, while the superficial cells tended to be significantly decreased. Regarding the percent change from the initial value, after 4 weeks in the MPA group, the KPI and superficial cells were significantly decreased, and the intermediate cells were significantly increased. The estrogen activity level and the progesterone concentration were significantly lower in the MPA group compared with the no MPA group. Conclusions. The MPA administration clearly lowered the estrogenic activity, indicating that MPA therapy should be effective in reducing the risk of TAM-associated endometrial cancer.
AB - Background: Postoperative adjuvant tamoxifen (TAM) therapy in breast cancer patients may lead, albeit rarely, to endometrial cancer. Preventive measures are urgently needed. Methods: The study subjects were postmenopausal women who had undergone surgery for breast cancer. The control group (n=10) received no further therapy. Patients who had completed adjuvant TAM therapy were assigned to a medroxy-progesterone acetate (MPA; 400 mg/day orally for 4 weeks) group (n=15) or no MPA treatment group (no MPA group) (n=15). Uterine cervix cytodiagnosis was performed after completing the TAM therapy (initial), and 4 (4-week) and 16 (16-week) weeks later. The serum 17β-estradiol (E2) and progesterone concentrations were measured initially and at 4 weeks. The karyopyknotic index (KPI), eosinophilic index (EI) and maturation index (MI) were calculated from Papanicolaou-stained specimens. Results: The background parameters showed no biases. There were no differences in the KPI or EI between the no MPA and MPA groups. However, regarding the MI, after 4 weeks in the MPA group, the intermediate cells were significantly increased, while the superficial cells tended to be significantly decreased. Regarding the percent change from the initial value, after 4 weeks in the MPA group, the KPI and superficial cells were significantly decreased, and the intermediate cells were significantly increased. The estrogen activity level and the progesterone concentration were significantly lower in the MPA group compared with the no MPA group. Conclusions. The MPA administration clearly lowered the estrogenic activity, indicating that MPA therapy should be effective in reducing the risk of TAM-associated endometrial cancer.
KW - Breast cancer
KW - Endometrial cancer
KW - Medroxyprogesterone acetate
KW - Tamoxifen
UR - http://www.scopus.com/inward/record.url?scp=77951508978&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77951508978&partnerID=8YFLogxK
U2 - 10.1007/BF02966959
DO - 10.1007/BF02966959
M3 - Article
AN - SCOPUS:77951508978
VL - 3
SP - 25
EP - 31
JO - Breast Cancer
JF - Breast Cancer
SN - 1340-6868
IS - 1
ER -